Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|April 1, 1981
Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylationT P Sloan, J R Idle, R L SmithCiba Foundation Symposium|January 1, 1980
Toxicological implications of polymorphic drug metabolismJ C Ritchie, T P Sloan, J R Idle, et al.British Medical Journal|September 2, 1978
Polymorphism of carbon oxidation of drugs and clinical implicationsT P Sloan, A Mahgoub, R Lancaster, et al.Journal of Medical Genetics|April 1, 1980
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British populationD A Evans, A Mahgoub, T P Sloan, et al.British Journal of Clinical Pharmacology|April 1, 1983
Genetically determined oxidation capacity and the disposition of debrisoquineT P Sloan, R Lancaster, R R Shah, et al.British Journal of Pharmacology|November 1, 1984
Genetic heterogeneity of histamine H2-receptors in the mouse vas deferensJ A Calvete, J L Donegan, R J Hayes, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|April 1, 1983
The metabolism of fenclofenac in the horseM V Marsh, J Caldwell, T P Sloan, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 1, 1980
A study of the debrisoquine hydroxylation polymorphism in a Nigerian populationC Mbanefo, E A Bababunmi, A Mahgoub, et al.Clinical Pharmacology and Therapeutics|November 1, 1979
Debrisoquin hydroxylation polymorphism among Ghanaians and CaucasiansN M Woolhouse, B Andoh, A Mahgoub, et al.British Journal of Clinical Pharmacology|August 1, 1983
The contribution of genetically determined oxidation status to inter-individual variation in phenacetin dispositionH W Devonshire, I Kong, M Cooper, et al.Pageof 2